The Rising Prevalence Of Candidiasis Infection To Boost The Candidiasis Market Growth
Candidiasis Market |
The Candidiasis
Market by Route of Administration (Injection, Ointment, and Oral), Drug
Type (Polyene, Azole, Echinocandin, and Other Drug Types), Anatomy Type (Oral
Candidiasis, Vulvovaginal Candidiasis, Cutaneous Candidiasis, Invasive
Candidiasis, and Systemic Candidiasis), End-users (Hospitals and Clinics,
Retail Pharmacies, and Other End-users), and Geography (North America, Europe,
Asia-Pacific, and Rest of the World) Size, Share, Outlook, and Opportunity
Analysis, 2023-2030
The global Candidiasis
Market is estimated to be valued at reach US$ 986.5 million in 2021 and is expected to exhibit a CAGR of 4.39 %
over the forecast period, as highlighted in a new report published by Coherent
Market Insights.
Market Overview:
Candidiasis is a fungal inflammation caused by a yeast
known as Candida. Few classes of Candida can led to inflammation
in individuals; the most frequent infection is Candida
albicans. Candida usually stays on the dermis and in the body, such
as the throat, mouth, skin, and vagina, without leading to any
difficulty.. Candida can lead to inflammation if it grows out of
control or if it goes deep inside the body.
Competitive
Landscape:
Key players involved in the growth of the
global Candidiasis Market are SCYNEXIS, Inc., Mycovia Pharmaceuticals, Inc., Basilea
Pharmaceutica Ltd, Pfizer Inc, Astellas Pharma Inc., NovaDigm Therapeutics, and
Viatris Inc.
Market Key Drivers:
The rising prevalence of Candidiasis
infection is expected to augment the growth of global Candidiasis Market. For instance, as per report by Nature in June
2021, there have been 2,739casese per 100,000 individuals suffering from
vulvovaginal candidiasis in Zimbabwe.
The rising cases of vaginitis is projected to
propel the growth of the global Candidiasis Market. For instance, as per PLOS
One in April 2022 vaginitis was known to affect 30% of vulvovaginal patients.
Covid-19 Impact
Analysis:
The Covi-19 outbreak had adversely affected
the growth of global candidiasis market mostly in the initial stage of pandemic
owing to the strict imposition of lockdown and shutdowns, worldwide trade was
affected severely, and the supply chain of pharma was interrupted, which impeded
the sales of candidiasis drugs and treatment.
Key Takeaways:
The global Candidiasis Market is anticipated to exhibit a CAGR of XX % during
the forecast period due to rising R&D for the expansion of treatment for
the RVV or VVC. For instance, in February 2021, SCYNEXIS, Inc., collaborated
with Amplity Health, to introduce Brexafemme in the U.S. for the treatment of
vaginal yeast infection.
Among regions, North America, Europe, and
Asia Pacific are expected to witness robust growth in the global Candidiasis Market due to rising
prevalence of RVV or VCC, increasing R&D, quick approvals and product
launches. For instance, as per PubMed, out of 12.3 million women in the IBM
MarketScan database 149,934 women were diagnosed with VVC in U.S.
Comments
Post a Comment